Stockreport

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

First Tracks Biotherapeutics, Inc. - Ordinary Shares  (TRAX) 
PDF First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runwayTrading of TRAX begins on Nasdaq today SAN DIEGO, April 20, 2026 (GLOBE NEWSWI [Read more]